Correlation between cholesterol absorption and atherogenic risk factors in hypercholesterolemic patients with type2 diabetes.

Correlation between cholesterol absorption and atherogenic risk factors in hypercholesterolemic patients with type2 diabetes. - The efficacy of inhibiting cholesterol absorption in hypercholesterolemic patients wiht type2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002070

Enrollment

120

Registered

2009-12-31

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemic patients with type2 diabetes

Interventions

Ezetimibe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: LDL-C>120mg/dL LDL-C<180mg/dL patients with type2 diabetes treating over 4weeks

Exclusion criteria

Exclusion criteria: HbA1c>10.0% or increasing or decreasing over 2% on HbA1c during past 3months patients with serious hepatic dysfunction Serum creatinine>2.0mg/dL Familyal hypercholesterolemia Pregnancy or Lactation

Design outcomes

Primary

Measure	Time frame
The efficacy of ezetimibe on LDL-cholesterol reduction.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026